Prab: Created page with "NOTOC {{Short description|Incretin therapy for weight loss, obesity medicine, type 2 diabetes, GLP-1 medications, GIP therapies, DPP-4 inhibitors, and W8MD medical weight loss care}} {{Infobox medical intervention | name = Incretin therapy | image = | caption = | specialty = Obesity medicine, endocrinology, medical weight loss, diabetes medicine | uses = Obesity, overweight, weight loss, type 2 diabetes..."

2026-06-28T12:16:44Z

Created page with "__NOTOC__ {{Short description|Incretin therapy for weight loss, obesity medicine, type 2 diabetes, GLP-1 medications, GIP therapies, DPP-4 inhibitors, and W8MD medical weight loss care}} {{Infobox medical intervention | name = Incretin therapy | image = | caption = | specialty = Obesity medicine, endocrinology, medical weight loss, diabetes medicine | uses = Obesity, overweight, weight loss, type 2 diabetes..."

New page

__NOTOC__
{{Short description|Incretin therapy for weight loss, obesity medicine, type 2 diabetes, GLP-1 medications, GIP therapies, DPP-4 inhibitors, and W8MD medical weight loss care}}
{{Infobox medical intervention
| name = Incretin therapy
| image =
| caption =
| specialty = [[Obesity medicine]], [[endocrinology]], [[medical weight loss]], [[diabetes medicine]]
| uses = [[Obesity]], [[overweight]], [[weight loss]], [[type 2 diabetes]], [[insulin resistance]], [[metabolic syndrome]], [[sleep apnea]]
| methods = [[GLP-1 receptor agonist]]s, [[GIP]]/[[GLP-1]] receptor agonists, oral [[GLP-1]] therapies, [[DPP-4 inhibitor]]s, lifestyle therapy
| medications = [[Semaglutide]], [[tirzepatide]], [[liraglutide]], [[dulaglutide]], [[orforglipron]], [[sitagliptin]], [[saxagliptin]]
| related = [[GLP-1]], [[GIP]], [[incretin mimetic]], [[GLP-1 weight loss]], [[W8MD Weight Loss, Sleep and MedSpa]]
}}

[[File:Confused.jpge|thumb|right|350px|Confused woman - W8MD can help.]]
[[File:Before-and-after-weight-loss.jpeg|thumb|right|300px|Modern incretin therapy has transformed physician-supervised [[weight loss]] and [[obesity medicine]].]]
[[File:Woman-losing-weight.jpeg|thumb|right|350px|Incretin medications may reduce appetite, increase satiety, and help eligible patients lose weight when combined with nutrition and follow-up care.]]
[[File:W8md weight loss sleep and medspa team.jpeg|thumb|right|350px|[[W8MD Weight Loss, Sleep and MedSpa]] can help eligible patients with incretin-based medical weight loss, including [[GLP-1 weight loss injections]].]]
[[File:W8md-meal-replacementnts.png|thumb|right|350px|[[Meal replacements]] may support incretin therapy by improving protein intake, portion control, and long-term [[weight loss maintenance]].]]
[[File:Sleep-apnea.png|thumb|right|350px|[[Zepbound]] is FDA-approved for moderate-to-severe [[obstructive sleep apnea]] in adults with obesity.]]

'''Incretin therapy''' refers to medications that mimic, enhance, or extend the effects of natural gut-derived hormones called '''[[incretin]]s'''. These hormones, especially [[glucagon-like peptide-1]] or [[GLP-1]] and [[glucose-dependent insulinotropic polypeptide]] or [[GIP]], help regulate appetite, blood sugar, insulin secretion, glucagon secretion, gastric emptying, satiety, and body weight.

Incretin-based medications are widely used for [[type 2 diabetes]] and are now central to modern [[obesity medicine]] and [[medical weight loss]]. For many patients, the most important use of incretin therapy is [[weight loss]], appetite control, [[GLP-1 maintenance therapy]], and reduction of weight-related complications such as [[prediabetes]], [[metabolic syndrome]], [[fatty liver disease]], [[hypertension]], and [[sleep apnea]]. Diabetes treatment remains an important second use, especially in patients with [[type 2 diabetes]], [[insulin resistance]], and elevated [[hemoglobin A1c]].

'''[[W8MD Weight Loss, Sleep and MedSpa]]''' can help eligible patients use incretin therapy safely and effectively as part of physician-supervised [[medical weight loss]]. W8MD offers [[GLP-1 weight loss injections]], newer oral incretin options when appropriate, [[nutrition]] support, [[meal replacements]], [[low-carbohydrate diet]] planning, [[sleep apnea]] screening, and long-term [[weight loss maintenance]].

==Overview==
Incretin therapy includes two major medication categories:

{{div col|colwidth=20em}}
* [[GLP-1 receptor agonist]]s and related incretin mimetics
* [[DPP-4 inhibitor]]s or incretin enhancers
{{div col end}}

For weight loss, the most powerful incretin therapies are [[GLP-1 receptor agonist]]s, dual [[GIP]]/[[GLP-1]] receptor agonists, and newer oral [[GLP-1]] medications. For diabetes, both GLP-1-based medications and DPP-4 inhibitors may help lower blood sugar, although DPP-4 inhibitors usually produce much less weight loss.

==What are incretins?==
'''Incretins''' are gut hormones released after eating. They help the body coordinate digestion, insulin secretion, appetite, and nutrient handling.

Important incretin-related hormones include:

{{div col|colwidth=18em}}
* [[GLP-1]]
* [[GIP]]
* [[Glucagon]]
* [[Amylin]]
{{div col end}}

The two best-known incretins are [[GLP-1]] and [[GIP]].

===GLP-1===
[[GLP-1]] is released from intestinal L cells after meals. It helps:

{{div col|colwidth=20em}}
* Stimulate glucose-dependent [[insulin]] secretion
* Reduce inappropriate [[glucagon]] secretion
* Slow gastric emptying
* Increase satiety
* Reduce appetite
* Improve post-meal blood sugar
* Support weight loss in pharmacologic doses
{{div col end}}

===GIP===
[[GIP]] is another incretin hormone released after eating. It influences insulin secretion, fat metabolism, and energy balance. [[Tirzepatide]] targets both [[GIP]] and [[GLP-1]] receptors.

==Mechanism of action==
Incretin therapies may work through several mechanisms:

{{div col|colwidth=20em}}
* Increased glucose-dependent insulin secretion
* Reduced glucagon secretion when glucose is elevated
* Slowed stomach emptying
* Increased fullness
* Reduced appetite
* Reduced food noise
* Reduced calorie intake
* Improved blood sugar after meals
* Improved insulin sensitivity indirectly through weight loss
* Improved cardiometabolic risk factors in selected patients
{{div col end}}

Because incretin medications act on appetite and satiety pathways, they can help patients who struggle with hunger, cravings, portion control, and repeated weight regain.

==Incretin therapy for weight loss==
Incretin therapy has become one of the most important developments in modern [[medical weight loss]]. For eligible patients with [[obesity]] or [[overweight]] with weight-related medical conditions, incretin medications may help produce clinically meaningful weight loss when used with nutrition, physical activity, sleep optimization, and long-term follow-up.

Weight-loss benefits may include:

{{div col|colwidth=18em}}
* Reduced hunger
* Reduced cravings
* Reduced food noise
* Smaller meal size
* Improved satiety
* Improved adherence to diet plans
* Improved [[blood pressure]] in some patients
* Improved [[blood sugar]] in some patients
* Improved [[triglycerides]] in some patients
* Improved [[sleep apnea]] severity in selected patients
* Improved long-term maintenance when continued and monitored
{{div col end}}

The FDA approved [[Zepbound]] or [[tirzepatide]] for chronic weight management in adults with obesity or overweight with at least one weight-related condition, in addition to reduced-calorie diet and increased physical activity.{{cite web|url=https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management|title=FDA Approves New Medication for Chronic Weight Management|publisher=U.S. Food and Drug Administration|date=November 8, 2023|accessdate=June 28, 2026}}

The FDA approved [[Wegovy]] to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight.{{cite web|url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or|title=FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight|publisher=U.S. Food and Drug Administration|date=March 8, 2024|accessdate=June 28, 2026}}

==Incretin therapy for type 2 diabetes==
Incretin therapy was first widely used for [[type 2 diabetes]]. In diabetes care, incretin medications can lower blood sugar by increasing glucose-dependent insulin secretion and reducing glucagon levels when blood glucose is elevated.

Diabetes benefits may include:

{{div col|colwidth=18em}}
* Lower fasting blood sugar
* Lower post-meal blood sugar
* Lower [[hemoglobin A1c]]
* Reduced need for some diabetes medications in selected patients
* Weight loss with GLP-1 and related therapies
* Cardiovascular benefit with selected GLP-1 medications
{{div col end}}

[[DPP-4 inhibitor]]s are mainly diabetes medications and are generally weight-neutral, while [[GLP-1 receptor agonist]]s and related incretin mimetics often produce weight loss.

==Types of incretin therapy==
===GLP-1 receptor agonists===
[[GLP-1 receptor agonist]]s, also called '''incretin mimetics''', are medications that directly activate GLP-1 receptors. They are used for [[type 2 diabetes]], [[obesity]], [[overweight]], and selected cardiovascular or sleep apnea indications depending on the medication.

Examples include:

{{div col|colwidth=18em}}
* [[Semaglutide]]
* [[Wegovy]]
* [[Ozempic]]
* [[Rybelsus]]
* [[Liraglutide]]
* [[Saxenda]]
* [[Victoza]]
* [[Dulaglutide]]
* [[Trulicity]]
* [[Exenatide]]
* [[Byetta]]
* [[Bydureon]]
* [[Lixisenatide]]
* [[Adlyxin]]
{{div col end}}

===Dual GIP and GLP-1 receptor agonists===
Dual incretin medications activate more than one incretin pathway. The best-known example is [[tirzepatide]], which activates [[GIP]] and [[GLP-1]] receptors.

Examples include:

{{div col|colwidth=18em}}
* [[Tirzepatide]]
* [[Mounjaro]]
* [[Zepbound]]
{{div col end}}

[[Mounjaro]] is used for [[type 2 diabetes]], while [[Zepbound]] is used for chronic weight management and moderate-to-severe [[obstructive sleep apnea]] in adults with obesity. The FDA approved Zepbound as the first medication for moderate-to-severe OSA in adults with obesity.{{cite web|url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea|title=FDA Approves First Medication for Obstructive Sleep Apnea|publisher=U.S. Food and Drug Administration|date=December 20, 2024|accessdate=June 28, 2026}}

===Oral GLP-1 receptor agonists===
Some incretin therapies are oral medications rather than injections.

Examples include:

{{div col|colwidth=18em}}
* [[Rybelsus]]
* [[Foundayo]]
* [[Orforglipron]]
{{div col end}}

The FDA approved [[Foundayo]] or [[orforglipron]] in 2026 to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight and at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity.{{cite web|url=https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026|title=Novel Drug Approvals for 2026|publisher=U.S. Food and Drug Administration|accessdate=June 28, 2026}}

FDA labeling describes Foundayo as [[orforglipron]] tablets for oral use with initial U.S. approval in 2026.{{cite web|url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf|title=FOUNDAYO orforglipron tablets prescribing information|publisher=U.S. Food and Drug Administration|accessdate=June 28, 2026}}

===DPP-4 inhibitors===
[[DPP-4 inhibitor]]s, also called '''incretin enhancers''', block the enzyme [[dipeptidyl peptidase-4]], which normally breaks down endogenous GLP-1 and GIP. By inhibiting DPP-4, these medications prolong natural incretin activity and help manage blood sugar after meals.

Examples include:

{{div col|colwidth=18em}}
* [[Sitagliptin]]
* [[Januvia]]
* [[Saxagliptin]]
* [[Onglyza]]
* [[Linagliptin]]
* [[Tradjenta]]
* [[Alogliptin]]
* [[Nesina]]
{{div col end}}

DPP-4 inhibitors are generally used for [[type 2 diabetes]] rather than weight loss. They are usually weight-neutral and do not produce the substantial weight loss seen with modern GLP-1 and GIP/GLP-1 medications.

A cardiovascular safety review notes that concerns have been raised about heart failure hospitalization with some DPP-4 inhibitors, especially saxagliptin, and that this may not be a uniform class effect.{{cite journal|last1=Kankanala|first1=S. R.|title=Cardiovascular safety of dipeptidyl peptidase-4 inhibitors|journal=Current Cardiology Reports|year=2016|pmc=4891459}}

==Comparison of incretin therapies==
{| class="wikitable"
! Medication class
! Examples
! Main use
! Weight-loss effect
! Route
|-
| [[GLP-1 receptor agonist]]s
| [[Semaglutide]], [[liraglutide]], [[dulaglutide]]
| [[Weight loss]], [[type 2 diabetes]], selected cardiovascular indications
| Moderate to substantial, depending on medication and dose
| Injection or oral for selected products
|-
| Dual [[GIP]]/[[GLP-1]] receptor agonists
| [[Tirzepatide]]
| [[Weight loss]], [[type 2 diabetes]], [[sleep apnea]] indication for Zepbound
| Substantial in eligible patients
| Injection
|-
| Oral [[GLP-1]] receptor agonists
| [[Rybelsus]], [[Foundayo]], [[orforglipron]]
| Diabetes or weight loss depending on product
| Variable; newer oral obesity products may produce clinically meaningful weight loss
| Oral tablet
|-
| [[DPP-4 inhibitor]]s
| [[Sitagliptin]], [[saxagliptin]], [[linagliptin]], [[alogliptin]]
| [[Type 2 diabetes]]
| Usually weight-neutral
| Oral tablet
|-
| Triple receptor agonists
| [[Retatrutide]]
| Investigational obesity and metabolic disease research
| Investigational; substantial weight reduction reported in phase 2 obesity trial
| Injection in studies
|}

==Approved incretin medications used in weight loss==
===Semaglutide===
[[Semaglutide]] is a [[GLP-1 receptor agonist]] used in products such as [[Wegovy]], [[Ozempic]], and [[Rybelsus]]. [[Wegovy]] is used for chronic weight management and selected cardiovascular risk-reduction indications. [[Ozempic]] and [[Rybelsus]] are primarily diabetes products.

===Tirzepatide===
[[Tirzepatide]] is a dual [[GIP]] and [[GLP-1]] receptor agonist used in [[Mounjaro]] and [[Zepbound]]. [[Mounjaro]] is used for [[type 2 diabetes]]. [[Zepbound]] is used for chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity.

===Liraglutide===
[[Liraglutide]] is a daily [[GLP-1 receptor agonist]]. [[Saxenda]] is used for chronic weight management, while [[Victoza]] is used for type 2 diabetes.

===Orforglipron===
[[Orforglipron]], marketed as [[Foundayo]], is an oral small-molecule [[GLP-1 receptor agonist]] approved for adults with obesity or overweight with weight-related medical conditions. It is used with reduced-calorie diet and increased physical activity.{{cite web|url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf|title=FOUNDAYO orforglipron tablets prescribing information|publisher=U.S. Food and Drug Administration|accessdate=June 28, 2026}}

==Emerging and investigational incretin drugs==
===Retatrutide===
[[Retatrutide]] is an investigational triple-hormone-receptor agonist that targets [[GIP]], [[GLP-1]], and [[glucagon]] receptors. A phase 2 trial published in the ''New England Journal of Medicine'' reported that retatrutide produced substantial weight reduction in adults with obesity over 48 weeks.{{cite journal|last1=Jastreboff|first1=A. M.|title=Triple-Hormone-Receptor Agonist Retatrutide for Obesity|journal=New England Journal of Medicine|year=2023|doi=10.1056/NEJMoa2301972|pmid=37366315}}

Retatrutide remains investigational unless and until approved by regulatory authorities for a specific indication. Patients should not buy research peptides or unapproved retatrutide products online.

===CagriSema===
[[CagriSema]] is an investigational combination of [[cagrilintide]] and [[semaglutide]]. Cagrilintide is an amylin analog, while semaglutide is a GLP-1 receptor agonist. This combination is being studied for obesity and metabolic disease.

===Amycretin===
[[Amycretin]] is an investigational medication designed to target both amylin and GLP-1 pathways. It is being studied as a potential obesity therapy.

===Other incretin combinations===
Future incretin therapies may combine GLP-1, GIP, glucagon, amylin, and other appetite or energy-balance pathways. These drugs may expand options for obesity medicine, diabetes care, and long-term maintenance.

==Metabolic and cardiovascular benefits==
Some incretin therapies provide benefits beyond weight loss and blood sugar control. Benefits may include:

{{div col|colwidth=18em}}
* Reduced body weight
* Lower [[hemoglobin A1c]]
* Improved [[blood pressure]]
* Improved [[triglycerides]]
* Improved waist circumference
* Improved [[insulin resistance]]
* Reduced cardiovascular events in selected patients
* Improved [[sleep apnea]] severity in selected adults with obesity using Zepbound
{{div col end}}

The FDA cardiovascular indication for Wegovy is important because it recognizes that selected GLP-1 therapy may reduce major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight.{{cite web|url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or|title=FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight|publisher=U.S. Food and Drug Administration|date=March 8, 2024|accessdate=June 28, 2026}}

==Side effects==
Common side effects of GLP-1 and related incretin therapies include:

{{div col|colwidth=18em}}
* Nausea
* Vomiting
* Diarrhea
* Constipation
* Abdominal discomfort
* Bloating
* Heartburn
* Reduced appetite
* Fatigue in some patients
* Injection-site reactions for injectable products
{{div col end}}

These side effects are often more common when starting therapy or increasing the dose. Eating smaller meals, avoiding greasy foods, staying hydrated, and dose adjustment under medical supervision may help.

==Safety considerations==
Incretin medications require medical supervision. They may not be appropriate for everyone.

Patients should discuss risks with a healthcare provider if they have:

{{div col|colwidth=20em}}
* History of [[pancreatitis]]
* [[Gallbladder disease]]
* Severe gastrointestinal disease
* [[Kidney disease]]
* [[Dehydration]] risk
* [[Diabetes]] using insulin or sulfonylureas
* Pregnancy or plans for pregnancy
* Breastfeeding
* Personal or family history of medullary thyroid carcinoma
* Multiple endocrine neoplasia syndrome type 2
* Eating disorder history
* Severe nausea or vomiting
{{div col end}}

FDA labeling for GLP-1 medications commonly includes warnings related to thyroid C-cell tumors observed in rodents, and patients should review product-specific prescribing information with their healthcare provider.

==Unapproved incretin products==
Patients should avoid unapproved online products marketed as [[semaglutide]], [[tirzepatide]], [[retatrutide]], [[cagrilintide]], or other research peptides. The FDA has warned about fraudulent compounded semaglutide and tirzepatide products marketed in the United States with false information on the label.{{cite web|url=https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss|title=FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss|publisher=U.S. Food and Drug Administration|accessdate=June 28, 2026}}

==How W8MD can help with incretin therapy==
[[W8MD Weight Loss, Sleep and MedSpa]] can help eligible patients determine whether incretin therapy is appropriate for [[weight loss]], [[obesity medicine]], metabolic health, or diabetes-related needs.

W8MD may help with:

{{div col|colwidth=20em}}
* Physician-supervised [[medical weight loss]]
* [[GLP-1 weight loss injections]]
* [[Semaglutide]] evaluation
* [[Wegovy]] evaluation
* [[Ozempic]] evaluation when appropriate
* [[Tirzepatide]] evaluation
* [[Mounjaro]] evaluation when appropriate
* [[Zepbound]] evaluation
* [[Foundayo]] evaluation when appropriate
* [[GLP-1 maintenance therapy]]
* Side-effect management
* Dose adjustment discussions
* [[Nutrition]] planning
* Protein planning
* [[Meal replacements]]
* [[Low-carbohydrate diet]]
* [[Ketogenic diet]]
* [[Sleep apnea]] screening
* [[Home sleep test]]
* [[CPAP]] support
* Long-term [[weight loss maintenance]]
{{div col end}}

==W8MD focus on weight loss first==
Although incretin therapy is important in diabetes care, W8MD’s main focus is helping patients lose weight and maintain weight loss. This matters because weight loss may improve many weight-related health problems, including:

{{div col|colwidth=18em}}
* [[Prediabetes]]
* [[Type 2 diabetes]]
* [[Insulin resistance]]
* [[Hypertension]]
* [[High cholesterol]]
* [[High triglycerides]]
* [[Fatty liver disease]]
* [[Sleep apnea]]
* [[PCOS]]
* [[Metabolic syndrome]]
* Joint pain
* Low energy
{{div col end}}

W8MD can also coordinate diabetes-related medication decisions with a patient’s primary care provider, endocrinologist, or other healthcare professionals when needed.

==Affordable W8MD incretin and GLP-1 options==
<div style="border:2px solid #f2c94c;background:#fff8df;padding:14px;margin:12px 0;border-radius:10px;">
'''Affordable incretin and GLP-1 weight loss options'''

W8MD offers [[GLP-1 weight loss injections]] and related incretin therapy options such as [[Wegovy]], [[Ozempic]], [[Zepbound]], [[Mounjaro]], [[semaglutide]], [[tirzepatide]], and newer oral options when medically appropriate.

* '''Affordable GLP-1 options starting at $29.99/week and up''' with insurance for visits for eligible patients.
* '''Most insurances accepted''' for qualifying medical visits.
* '''Self-pay GLP-1 injection options starting from $59.99/week and up''' when available and medically appropriate.
* Pricing, insurance coverage, medication access, prior authorization, and eligibility vary by patient, location, medication, pharmacy availability, and medical evaluation.
</div>

==W8MD locations==
W8MD serves patients from New York City and Philadelphia offices, with service areas extending across the Northeast and Mid-Atlantic region.

{| class="wikitable" style="width:100%;"
! Location
! Address
! Phone
! Services
! Map
|-
| '''[[NYC medical weight loss|Brooklyn / New York City Weight Loss Center]]'''
| 2632 E 21st Street, Suite L3, Brooklyn, NY 11235
| (718) 946-5500
| [[Medical weight loss]], [[GLP-1 weight loss injections]], [[sleep medicine]], [[MedSpa]], [[nutrition]]
| [https://www.google.com/maps/search/?api=1&query=2632+E+21st+Street+Ste+L3+Brooklyn+NY+11235 View map]
|-
| '''[[Philadelphia weight loss doctor|Philadelphia / Greater Philadelphia Weight Loss Center]]'''
| 1718 Welsh Road, 2nd Floor, Suite C, Philadelphia, PA 19115
| (215) 676-2334
| [[Medical weight loss]], [[GLP-1 weight loss injections]], [[sleep medicine]], [[nutrition]], wellness services
| [https://www.google.com/maps/search/?api=1&query=1718+Welsh+Road+2nd+Floor+Ste+C+Philadelphia+PA+19115 View map]
|}

==Service areas==
{{div col|colwidth=18em}}
* [[New York City weight loss]]
* [[Greater New York City weight loss]]
* [[Brooklyn weight loss]]
* [[Manhattan weight loss]]
* [[Queens weight loss]]
* [[Staten Island weight loss]]
* [[Long Island weight loss]]
* [[Connecticut weight loss]]
* [[New Jersey weight loss]]
* [[Philadelphia weight loss]]
* [[Greater Philadelphia weight loss]]
* [[Northeast Philadelphia weight loss]]
* [[Delaware weight loss]]
* [[Bucks County weight loss]]
* [[Montgomery County PA weight loss]]
* [[Delaware County PA weight loss]]
{{div col end}}

==Who may benefit from incretin therapy?==
Incretin therapy may be considered for eligible patients with:

{{div col|colwidth=18em}}
* [[Obesity]]
* [[Overweight]]
* BMI of 30 or higher
* BMI of 27 or higher with weight-related medical problems
* [[Prediabetes]]
* [[Type 2 diabetes]]
* [[Insulin resistance]]
* [[Metabolic syndrome]]
* [[Hypertension]]
* [[Dyslipidemia]]
* [[Fatty liver disease]]
* [[PCOS]]
* [[Sleep apnea]]
* Repeated weight regain
* Strong hunger or cravings
* Need for medical weight loss support
{{div col end}}

==Incretin therapy and maintenance==
A major challenge after successful weight loss is preventing regain. Many patients need a maintenance plan after reaching goal weight or near-goal weight.

Maintenance strategies may include:

{{div col|colwidth=18em}}
* Continued GLP-1 or incretin therapy when appropriate
* Lowest effective dose
* [[GLP-1 maintenance therapy]]
* Protein-first nutrition
* [[Strength training]]
* [[Meal replacements]]
* Sleep apnea treatment
* Regular follow-up
* Weekly weight monitoring
* Early intervention for regain
{{div col end}}

==Frequently asked questions==
===What is incretin therapy?===
Incretin therapy uses medications that mimic or enhance gut hormones such as GLP-1 and GIP to improve appetite control, satiety, insulin secretion, glucagon regulation, and blood sugar control.

===Is incretin therapy mainly for weight loss or diabetes?===
Historically, incretin therapy was mainly used for type 2 diabetes. Today, GLP-1 and related incretin medications are also major tools in medical weight loss and obesity medicine.

===What is the difference between GLP-1 medications and DPP-4 inhibitors?===
GLP-1 medications directly activate GLP-1 receptors and can produce significant weight loss. DPP-4 inhibitors prolong the body’s natural incretin hormones and mainly help with blood sugar control, usually without major weight loss.

===Can W8MD help with incretin therapy for weight loss?===
Yes. W8MD can evaluate eligible patients for incretin-based medical weight loss, including GLP-1 injections, oral options when appropriate, nutrition support, sleep apnea screening, and long-term maintenance.

===Can incretin therapy help diabetes?===
Yes. Incretin therapies can improve blood sugar control in type 2 diabetes. Patients with diabetes should use these medications under medical supervision, especially if they take insulin or sulfonylureas.

===Are incretin medications safe?===
They can be safe and effective for selected patients but require medical evaluation, correct dosing, monitoring for side effects, and attention to contraindications.

===Is retatrutide available?===
Retatrutide is investigational unless approved by regulatory authorities in the future. Patients should not buy unapproved research peptides online.

===Does W8MD help with sleep apnea related to obesity?===
Yes. W8MD can screen for sleep apnea, arrange home sleep testing when appropriate, and help eligible adults with obesity and moderate-to-severe OSA evaluate Zepbound when medically appropriate.

==Conclusion==
Incretin therapy has transformed the treatment of [[obesity]], [[overweight]], [[type 2 diabetes]], and cardiometabolic risk. GLP-1 receptor agonists, dual GIP/GLP-1 agonists, oral GLP-1 medications, DPP-4 inhibitors, and emerging investigational agents all work through gut hormone pathways, but their effects on weight loss and blood sugar differ. For W8MD patients, incretin therapy is especially important as a tool for physician-supervised weight loss, appetite control, GLP-1 maintenance, sleep apnea risk reduction, and long-term health improvement. [[W8MD Weight Loss, Sleep and MedSpa]] can help eligible patients choose safe, evidence-based incretin options and combine them with nutrition, sleep care, and maintenance support.

==See also==
{{div col|colwidth=18em}}
* [[Incretin]]
* [[GLP-1]]
* [[GIP]]
* [[GLP-1 receptor agonist]]
* [[DPP-4 inhibitor]]
* [[GLP-1 weight loss]]
* [[Weight loss injections]]
* [[Medical weight loss]]
* [[Obesity medicine]]
* [[Semaglutide]]
* [[Wegovy]]
* [[Ozempic]]
* [[Rybelsus]]
* [[Tirzepatide]]
* [[Mounjaro]]
* [[Zepbound]]
* [[Foundayo]]
* [[Orforglipron]]
* [[Liraglutide]]
* [[Saxenda]]
* [[Victoza]]
* [[Dulaglutide]]
* [[Trulicity]]
* [[Sitagliptin]]
* [[Januvia]]
* [[Saxagliptin]]
* [[Onglyza]]
* [[Retatrutide]]
* [[CagriSema]]
* [[Type 2 diabetes]]
* [[Insulin resistance]]
* [[Sleep apnea]]
* [[W8MD Weight Loss, Sleep and MedSpa]]
{{div col end}}

==Relevant WikiMD links==
* [https://wikimd.org/wiki/GLP-1 GLP-1 on WikiMD]
* [https://wikimd.org/wiki/GLP-1_receptor_agonist GLP-1 receptor agonist on WikiMD]
* [https://wikimd.org/wiki/Semaglutide Semaglutide on WikiMD]
* [https://wikimd.org/wiki/Tirzepatide Tirzepatide on WikiMD]
* [https://wikimd.org/wiki/Zepbound Zepbound on WikiMD]
* [https://wikimd.org/wiki/Wegovy Wegovy on WikiMD]
* [https://wikimd.org/wiki/Ozempic Ozempic on WikiMD]
* [https://wikimd.org/wiki/Mounjaro Mounjaro on WikiMD]
* [https://wikimd.org/wiki/Medical_weight_loss Medical weight loss on WikiMD]
* [https://wikimd.org/wiki/Weight_loss Weight loss on WikiMD]
* [https://wikimd.org/wiki/Type_2_diabetes Type 2 diabetes on WikiMD]
* [https://wikimd.org/wiki/Sleep_apnea Sleep apnea on WikiMD]

==Further reading==
* {{cite web|url=https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management|title=FDA Approves New Medication for Chronic Weight Management|publisher=U.S. Food and Drug Administration|date=November 8, 2023|accessdate=June 28, 2026}}
* {{cite web|url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or|title=FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight|publisher=U.S. Food and Drug Administration|date=March 8, 2024|accessdate=June 28, 2026}}
* {{cite web|url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea|title=FDA Approves First Medication for Obstructive Sleep Apnea|publisher=U.S. Food and Drug Administration|date=December 20, 2024|accessdate=June 28, 2026}}
* {{cite web|url=https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026|title=Novel Drug Approvals for 2026|publisher=U.S. Food and Drug Administration|accessdate=June 28, 2026}}
* {{cite web|url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf|title=FOUNDAYO orforglipron tablets prescribing information|publisher=U.S. Food and Drug Administration|accessdate=June 28, 2026}}
* {{cite journal|last1=Jastreboff|first1=A. M.|title=Triple-Hormone-Receptor Agonist Retatrutide for Obesity|journal=New England Journal of Medicine|year=2023|doi=10.1056/NEJMoa2301972|pmid=37366315}}
* {{cite journal|last1=Kankanala|first1=S. R.|title=Cardiovascular safety of dipeptidyl peptidase-4 inhibitors|journal=Current Cardiology Reports|year=2016|pmc=4891459}}

==External links==
* [https://www.w8mdspa.com W8MD Weight Loss, Sleep and Medspa Centers]
* [https://nycmedicalweightloss.com NYC medical weight loss]
* [https://w8md.org Philadelphia medical weight loss]
* [https://wikimd.org/wiki/GLP-1 GLP-1 on WikiMD]
* [https://wikimd.org/wiki/Semaglutide Semaglutide on WikiMD]
* [https://wikimd.org/wiki/Tirzepatide Tirzepatide on WikiMD]
* [https://wikimd.org/wiki/Medical_weight_loss Medical weight loss on WikiMD]
* [https://wikimd.org/wiki/Type_2_diabetes Type 2 diabetes on WikiMD]

{{GLP-1}}
{{DEFAULTSORT:Incretin Therapy}}
[[Category:Incretin therapy]]
[[Category:Incretins]]
[[Category:GLP-1]]
[[Category:GLP-1 receptor agonists]]
[[Category:GLP-1 weight loss]]
[[Category:GIP]]
[[Category:DPP-4 inhibitors]]
[[Category:Weight loss injections]]
[[Category:Medical weight loss]]
[[Category:Obesity medicine]]
[[Category:Anti-obesity medication]]
[[Category:Semaglutide]]
[[Category:Tirzepatide]]
[[Category:Wegovy]]
[[Category:Ozempic]]
[[Category:Rybelsus]]
[[Category:Mounjaro]]
[[Category:Zepbound]]
[[Category:Foundayo]]
[[Category:Orforglipron]]
[[Category:Liraglutide]]
[[Category:Dulaglutide]]
[[Category:Sitagliptin]]
[[Category:Saxagliptin]]
[[Category:Retatrutide]]
[[Category:CagriSema]]
[[Category:Type 2 diabetes]]
[[Category:Insulin resistance]]
[[Category:Metabolic syndrome]]
[[Category:Sleep apnea]]
[[Category:W8MD]]

Incretin therapy - Revision history

Prab at 12:30, 28 June 2026

← Older revision		Revision as of 12:30, 28 June 2026
Line 17:		Line 17:
	[[File:W8md weight loss sleep and medspa team.jpeg\|thumb\|right\|350px\|[[W8MD Weight Loss, Sleep and MedSpa]] can help eligible patients with incretin-based medical weight loss, including [[GLP-1 weight loss injections]].]]		[[File:W8md weight loss sleep and medspa team.jpeg\|thumb\|right\|350px\|[[W8MD Weight Loss, Sleep and MedSpa]] can help eligible patients with incretin-based medical weight loss, including [[GLP-1 weight loss injections]].]]
	[[File:W8md-meal-replacementnts.png\|thumb\|right\|350px\|[[Meal replacements]] may support incretin therapy by improving protein intake, portion control, and long-term [[weight loss maintenance]].]]		[[File:W8md-meal-replacementnts.png\|thumb\|right\|350px\|[[Meal replacements]] may support incretin therapy by improving protein intake, portion control, and long-term [[weight loss maintenance]].]]
	[[File:Sleep-apnea.png\|thumb\|right\|350px\|[[Zepbound]] is FDA-approved for moderate-to-severe [[obstructive sleep apnea]] in adults with obesity.]]		[[File:Sleep apnea.png\|thumb\|right\|350px\|[[Zepbound]] is FDA-approved for moderate-to-severe [[obstructive sleep apnea]] in adults with obesity.]]

	'''Incretin therapy''' refers to medications that mimic, enhance, or extend the effects of natural gut-derived hormones called '''[[incretin]]s'''. These hormones, especially [[glucagon-like peptide-1]] or [[GLP-1]] and [[glucose-dependent insulinotropic polypeptide]] or [[GIP]], help regulate appetite, blood sugar, insulin secretion, glucagon secretion, gastric emptying, satiety, and body weight.		'''Incretin therapy''' refers to medications that mimic, enhance, or extend the effects of natural gut-derived hormones called '''[[incretin]]s'''. These hormones, especially [[glucagon-like peptide-1]] or [[GLP-1]] and [[glucose-dependent insulinotropic polypeptide]] or [[GIP]], help regulate appetite, blood sugar, insulin secretion, glucagon secretion, gastric emptying, satiety, and body weight.